Home > Healthcare > Pharmaceuticals > Finished Drug Form > Hyperlipidemia Drugs Market
Hyperlipidemia Drugs Market Size
- Report ID: GMI10320
- Published Date: Jul 2024
- Report Format: PDF
Hyperlipidemia Drugs Market Size
Hyperlipidemia Drugs Market size was valued at around USD 21.6 billion in 2023 and is estimated to grow at 3.2% CAGR from 2024 to 2032. Hyperlipidemia drugs are medications used to treat hyperlipidemia, a condition characterized by abnormally high levels of lipid and fats in the blood, such as cholesterol and triglycerides. These drugs aim to lower lipid levels to reduce the risk of cardiovascular diseases, including heart attack and stroke.
The rising prevalence of cardiovascular diseases is a significant driving factor for the market. For instance, according to a study published by National Library of Medicine in January 2024, coronary artery disease (CAD) accounts for approximately 6,10,000 deaths annually (estimated 1 in 4 deaths) and is the leading cause of mortality in the U.S. Also, it is third leading cause of mortality worldwide and is associated with 17.8 million deaths annually. This underscores the critical need for effective hyperlipidemia drugs to manage lipid levels and reduce the risk of cardiovascular events.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Hyperlipidemia Drugs Market Size in 2023: | USD 21.6 Billion |
| Forecast Period: | 2024 - 2032 |
| Forecast Period 2024 - 2032 CAGR: | 3.2% |
| 2032 Value Projection: | USD 28.5 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 210 |
| Tables, Charts & Figures: | 284 |
| Segments covered: | Type, Drug Class, Route of Administration, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Furthermore, rising prevalence of hyperlipidemia, advancements in drug development, and rising geriatric population are also among the key factors promoting the growth of the market.
Frequently Asked Questions (FAQ) :
Hyperlipidemia Drugs Market Scope
